- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy in Advanced Biliary Tract Cancers
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 7, Pages 1569
Publisher
MDPI AG
Online
2021-03-30
DOI
10.3390/cancers13071569
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Response Rates to Anti–PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase
- (2021) Cristina Valero et al. JAMA Oncology
- Global incidence of and trends in intrahepatic and extrahepatic cholangiocarcinoma from 1993 to 2012
- (2020) Andrea A. Florio et al. CANCER
- Top 10 Challenges in Cancer Immunotherapy
- (2020) Priti S. Hegde et al. IMMUNITY
- A pilot study of durvalumab/tremelimumab (durva/treme) and radiation (XRT) for metastatic biliary tract cancer (mBTC): Preliminary safety and efficacy.
- (2020) Theodore S. Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
- (2020) Sarina A. Piha-Paul et al. INTERNATIONAL JOURNAL OF CANCER
- Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC).
- (2020) Do-Youn Oh et al. JOURNAL OF CLINICAL ONCOLOGY
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
- (2020) Richard D. Kim et al. JAMA Oncology
- Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers
- (2020) Oliver Klein et al. JAMA Oncology
- Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma
- (2020) Jianzhen Lin et al. Hepatobiliary Surgery and Nutrition
- 73P Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
- (2020) C. Yoo et al. ANNALS OF ONCOLOGY
- 53P Toripalimab with chemotherapy as first-line treatment for advanced biliary tract tumors: A preliminary analysis of safety and efficacy of an open-label phase II clinical study
- (2020) T. Liu et al. ANNALS OF ONCOLOGY
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial
- (2020) Alice Boilève et al. EUROPEAN JOURNAL OF CANCER
- Recent advances of immunotherapy for biliary tract cancer
- (2020) Alessandro Rizzo et al. Expert Review of Gastroenterology & Hepatology
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
- (2019) Jérôme Galon et al. NATURE REVIEWS DRUG DISCOVERY
- Cholangiocarcinoma: Epidemiology and risk factors
- (2019) Shahid A. Khan et al. LIVER INTERNATIONAL
- Clinical presentation, diagnosis and staging of cholangiocarcinoma
- (2019) Alejandro Forner et al. LIVER INTERNATIONAL
- Anatomical, histomorphological, and molecular classification of cholangiocarcinoma
- (2019) Timothy Kendall et al. LIVER INTERNATIONAL
- Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma
- (2019) Paola Bertuccio et al. JOURNAL OF HEPATOLOGY
- Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).
- (2019) Tatsuya Ioka et al. JOURNAL OF CLINICAL ONCOLOGY
- Liver-Resident NK Cells Control Antiviral Activity of Hepatic T Cells via the PD-1-PD-L1 Axis
- (2019) Jing Zhou et al. IMMUNITY
- A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC).
- (2019) Aparna Raj Parikh et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.
- (2019) Yung-Jue Bang et al. JOURNAL OF CLINICAL ONCOLOGY
- ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
- (2019) Angela Lamarca et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC).
- (2019) Richard D. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases
- (2019) Osama M. Alshari et al. OncoTargets and Therapy
- The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity
- (2019) Sangeetha Palakurthi et al. Cancer Immunology Research
- Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis
- (2019) Oliver Clements et al. JOURNAL OF HEPATOLOGY
- Risk Factors and Outcomes of Early Relapse After Curative Resection of Intrahepatic Cholangiocarcinoma
- (2019) Hua Yang et al. Frontiers in Oncology
- Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
- (2019) Makoto Ueno et al. Lancet Gastroenterology & Hepatology
- 102PCo-occurrence of NTRK fusions with other genomic biomarkers in cancer patients
- (2019) X Jiao et al. ANNALS OF ONCOLOGY
- 1272PLenvatinib plus PD-1 blockade in advanced bile tract carcinoma
- (2019) J Lin et al. ANNALS OF ONCOLOGY
- 1174OPembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies
- (2019) L A Diaz et al. ANNALS OF ONCOLOGY
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting cholangiocarcinoma
- (2018) Joachim C. Mertens et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Comprehensive molecular profiling of intra- and extrahepatic cholangiocarcinomas: potential targets for intervention
- (2018) Maeve A Lowery et al. CLINICAL CANCER RESEARCH
- The Immune Landscape of Cancer
- (2018) Vésteinn Thorsson et al. IMMUNITY
- Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations
- (2018) Christopher P. Wardell et al. JOURNAL OF HEPATOLOGY
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- The prognostic value of portal vein and hepatic artery involvement in patients with perihilar cholangiocarcinoma
- (2018) Jeroen L.A. van Vugt et al. HPB
- Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair
- (2018) Angela Lamarca et al. CANCER TREATMENT REVIEWS
- The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium
- (2018) Alessandra Gentilini et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- 757PM7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial
- (2018) C Yoo et al. ANNALS OF ONCOLOGY
- Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma
- (2018) Benjamin Goeppert et al. BRITISH JOURNAL OF CANCER
- Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma
- (2018) Christof C. Smith et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor mutational burden (TMB) and co-existing actionable mutations in biliary tract cancers (BTC).
- (2017) Apurva Jain et al. JOURNAL OF CLINICAL ONCOLOGY
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- New Horizons for Precision Medicine in Biliary Tract Cancers
- (2017) Juan W. Valle et al. Cancer Discovery
- Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
- (2017) Apinya Jusakul et al. Cancer Discovery
- PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
- (2017) Jacqueline Fontugne et al. Oncotarget
- Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
- (2017) Kaichao Feng et al. Protein & Cell
- Activation or suppression of the immune response mediators in biliary tract cancer (BTC) patients: a systematic review and meta-analysis
- (2017) Ying Wang et al. Journal of Cancer
- Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
- (2017) Paul C. Tumeh et al. Cancer Immunology Research
- Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) J. W. Valle et al. ANNALS OF ONCOLOGY
- Biliary cancer: Utility of next-generation sequencing for clinical management
- (2016) Milind Javle et al. CANCER
- Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
- (2016) Jesus M. Banales et al. Nature Reviews Gastroenterology & Hepatology
- Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999–2007: Results of EUROCARE-5
- (2015) Côme Lepage et al. EUROPEAN JOURNAL OF CANCER
- Genomic spectra of biliary tract cancer
- (2015) Hiromi Nakamura et al. NATURE GENETICS
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune tolerance in liver disease
- (2014) Ian N. Crispe HEPATOLOGY
- Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma
- (2014) Rondell P. Graham et al. HUMAN PATHOLOGY
- Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer
- (2014) Atsushi Aruga et al. Journal of Translational Medicine
- Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer
- (2013) A. Aruga et al. CLINICAL CANCER RESEARCH
- Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes
- (2013) Daniela Sia et al. GASTROENTEROLOGY
- Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma
- (2013) Yasuhito Arai et al. HEPATOLOGY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Intratumoral IL-17+ Cells and Neutrophils show Strong Prognostic Significance in Intrahepatic Cholangiocarcinoma
- (2012) Fang-Ming Gu et al. ANNALS OF SURGICAL ONCOLOGY
- Treatment of recurrent intrahepatic cholangiocarcinoma
- (2012) L. Sulpice et al. BRITISH JOURNAL OF SURGERY
- Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
- (2012) Benjamin R. Kipp et al. HUMAN PATHOLOGY
- Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
- (2011) M Miyamoto et al. BRITISH JOURNAL OF CANCER
- Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
- (2011) D. R. Borger et al. ONCOLOGIST
- Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer
- (2010) Miho Kaida et al. JOURNAL OF IMMUNOTHERAPY
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma
- (2008) Alphonse E Sirica WORLD JOURNAL OF GASTROENTEROLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now